|
|
|
|
|
Dipyridamole
drug data and news
Dipyridamole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Dipyridamole | ||
| Brand Names/Synonyms | Aggrenox; Agilease; Anginal; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apricor; Cardioflux; Cardoxil; Cardoxin; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantyl; Dipiridamol; Dipyridamine; Dipyridamol; Dipyridamole; Dipyridamole, Pharma; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Iv Persantine; Justpertin; Kurantil; Natyl; Novo-Dipiradol; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Prandiol 75; Protangix; RA 8; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12 | ||
| Indication | For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis. | ||
| Mechanism Of Action | Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation. | ||
| Dipyridamole News (When available) |
Anti-Platelet Use Reduces Stroke Severity and Improves Outcomes in ... Feb 20, 2006 Secondary Stroke Prevention Guidelines Call for Upgrade of TIA ... Feb 21, 2006 CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 ... Jan 30, 2006 Dipyridamole, ASA and warding off stroke Oct 26, 2005 PET and PET-CT: Expanding the Scope of Cardiovascular Imaging Aug 23, 2005 THE FAMILY DOCTOR Aug 23, 2005 Review: Dipyridamole Given With or Without Aspirin Reduces ... Jul 24, 2005 Value of absence of a transient myocardial perfusion defect during ... Jul 15, 2005 Noninvasive Diagnosis of Coronary Artery Disease in Patients With ... Jul 9, 2005 The Many Ways to Myocardial Perfusion Imaging Jun 12, 2005 Noninvasive Diagnosis of Coronary Artery Disease in Patients With ... Jul 9, 2005 Assessment of Myocardial Viability in Chronic Ischemic Heart ... Jun 12, 2005 The Many Ways to Myocardial Perfusion Imaging Jun 12, 2005 Assessment of Myocardial Viability in Chronic Ischemic Heart ... Jun 12, 2005 NICE Recommends Aggrenox (dipyridamol) as First Line Treatment for ... Jun 6, 2005 Brain Attack A Look at Stroke Prevention and Treatment May 13, 2005 UK Centres Lead Trial to Evaluate Modern Stent Technologies Over ... Apr 28, 2005 UK Centres Lead Trial to Evaluate Modern Stent Technologies Over ... 28 Apr 2005 Oral Antiplatelet Therapy Feb 15, 2005 Oral Antiplatelet Therapy—Reply Feb 15, 2005 Assessment of minimally invasive direct coronary artery bypass ... Mar 4, 2005 Stroke Prevention Guidelines From the National Stroke Association Feb 22, 2005 | ||
| Dosage Forms | tablets | ||
| Drug_Category | Vasodilator Agents; Vasodilator Agents; ATC:B01AC07 | ||
| Absorption | 70% | ||
| Interactions |
Interactions for Dipyridamole: No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE® (dipyridamole USP) Tablets. The following information was obtained from the literature. Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. | ||
| Toxicity | Hypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-[[3-[bis(2-hydroxyethyl)amino]-5,10-bis(1-piperidyl)-2,4,7,9-tetrazabicyclo[4.4.0]deca-2,4,7,9,11-pentaen-8-yl]-(2-hydroxyethyl)amino]ethanol | ||
| Chemical Formula | C24H40N8O4 | ||
| Molecular Weight | 504.626 g/mol | ||
| Smiles String | C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO | ||
| Melting Point | 163°C | ||
| Water Solubility | Slightly | ||
| State | solid | ||
| LogP/Hphobicity | -0.01 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | hepatic | ||
| Half Life | 40 minutes | ||
| Protein Binding [%] | 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Dipyridamole.html http://www.rxlist.com/cgi/generic2/dipyrid.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00360 | ||
| CAS Registry Number | 58-32-2 | ||
| KEGG Compound ID | C06964 | ||
| PubChem ID | SID:148864 | ||
| PharmGKB ID | PA449367 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2244475 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |